Back to mobile site

Maxim Group Reiterates Buy on Abeona Therapeutics (ABEO) Following ABO-102 Update

February 17, 2017 2:29 PM EST Send to a Friend
Maxim Group reiterated a Buy rating and $14.00 price target on Abeona Therapeutics (NASDAQ: ABEO) following the company's ABO-102 update ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login